BioWorld

Feb. 1, 2007

Palatin Partners With AstraZenca In $310M Obesity Program Deal

In its second major collaboration involving melanocortin receptors, Palatin Technologies Inc. signed a potential $310 million deal with AstraZeneca plc to develop small-molecule compounds for obesity and other metabolic disorders. (BioWorld Today) Read More

Argenta Changeover Complete With Deal Worth Up To $500M

In Graft-Vs.-Host, Picking The Winners May Become Easier

HIV Microbicide Trials Stopped, Dropping Polydex's Stock Prices

YM Biosciences Suffers Setback With Stop Of Tesmilifene Trial

Repros Therapeutics Raising $36M On Positive Interim Data

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for June 10, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors

BioWorld Science

Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.

Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors

BioWorld Science

Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...